Specialty Pharmacy

Three new studies looked at the mechanisms involved in tissue damage related to rheumatoid arthritis and lupus.

FOXA1 has been previously known to be mutated in prostate cancer; however, its biological functions were not understood well.

Top news of the day from across the health care landscape.

Aptevo Therapeutics announced the launch of its new vial size for its coagulation factor IX recombinant (Ixinity) treatment for hemophilia B in the US market.

A recent study showed that adherence to prophylaxis for severe hemophilia A can improve a patient’s physical performance.

Top news of the day from across the health care landscape.

Specific types of cancer—such as bone, kidney, throat, and uterine—also had a higher incidence of chronic and severe pain that restricted daily activity.

Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.

Top news of the day from across the health care landscape.

Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria.

Technology solutions such as CourMed will allow better pharmacist-patient communication, adherence, and overall improved patient outcomes.

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.

First-line treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) demonstrated overall and progression-free long-term survival benefits in patients with BRAF-mutation positive melanoma.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

Officials with the FDA have approved Dova Pharmaceuticals’ supplemental New Drug Application (sNDA) for expanding the use of avatrombopag (Doptelet).

Data from a phase 2 study demonstrated that topical ruxolitinib cream significantly improved repigmentation of facial lesions in adults with vitiligo.

Top news of the day from across the health care landscape.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses the journey of implementing specialty pharmacy services in a health system.

Dupilumab (Dupixent) is the first biologic medicine approved for inadequately controlled chronic rhinosinusitis with nasal polyposis.

To date, the Ohio audit is the first comprehensive review of PBM practices and incorporated 39 million drug transactions, the authors said.

The recently-finalized CMS drug pricing rule excluded direct and indirect remuneration fee reform.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.

Top news of the day from across the health care landscape.

The new syringe is designed to improve the subcutaneous administration of lanreotide (Somatuline Depot, Ipsen Biopharmaceuticals).